Amgenbd
Amgen is a biotechnological company that is focused on discovering, developing and manufacturing therapeutics for serious illnesses.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Amgenbd Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
2,886,040Website Global Rank
5,858Website Monthly Traffic
Twitter Followers
Description
Amgen is a biotechnological company that is focused on discovering, developing and manufacturing therapeutics for serious illnesses.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2012 | Gamida Cell | Series E | 0 |
| 7/2022 | Kernal Biologics | Series A | 0 |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 5/2015 | Precision BioSciences | Series A | 0 |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 2/2015 | Viridian Therapeutics | Series B | 0 |
| 1/2021 | NoviSci | Seed Round | - |
| 7/2018 | Alector | Series E | 133M |
| 11/2017 | Syapse | Series D | 0 |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 8/2021 | Catena Biosciences | Pre Seed Round | 0 |
| 3/2016 | Tizona Therapeutics | Series B | 43M |
| 8/2011 | Ardelyx | Series B | 30M |
| 10/2017 | Kymera Therapeutics | Series A | 30M |
| 6/2009 | Viridian Therapeutics | Series A | 4M |
| 2/2018 | Senti Biosciences | Series A | 53M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 1/2008 | Calistoga Pharmaceuticals | Series A | 5.2M |
| 3/2022 | CancerIQ | Series B | 14M |
| 8/2007 | Accelerator Corp. | Series C | 22.5M |
| 4/2019 | NAVAN Technologies | Seed Round | - |
| 1/2014 | Atara Biotherapeutics | Series B | 13.5M |
| 12/2013 | Sutro Biopharma | Series D | 0 |
| 7/2006 | Trinity Biosystems | Series B | 21M |
| 6/2007 | Argolyn Bioscience | Series A | 15.8M |
| 7/2022 | BigHat Biosciences | Series B | 0 |
| 3/2020 | GPB Scientific | Venture Round | 25.5M |
| 5/2022 | TileDB | Venture Round | - |
| 1/2004 | ViaCell | Venture Round | 20M |
| 9/2010 | DecImmune Therapeutics | Venture Round | 3.2M |
| 7/2020 | BeiGene | Post-IPO Equity | 2.1B |
| 1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
| 8/2017 | GNS Healthcare | Venture Round | 6M |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 9/2022 | ImmunoScape | Venture Round | 14M |
| 5/2012 | Sutro Biopharma | Series C | 16.5M |
| 4/2021 | ImmunoSCAPE | Venture Round | 14M |
| 6/2022 | ReCode Therapeutics | Series B | 0 |
| 8/2011 | Oncofactor | Series A | 2.1M |
| 3/2006 | Theraclone Sciences | Series A | 0 |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 1/2011 | Acylin Therapeutics | Series A | 4.4M |
| 11/2018 | Kymera Therapeutics | Series B | 65M |
| 9/2020 | Carmot Therapeutics | Series C | 47M |
| 5/2005 | Avidia | Series B | 28.5M |
| 2/2020 | EnClear Therapies | Series A | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 5/2020 | QurAlis | Series A | 0 |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 8/2008 | InteKrin | Series C | 0 |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 11/2010 | Sutro Biopharma | Series C | 36.5M |
| 4/2018 | QurAlis | Seed Round | - |
| 12/2020 | DJS Antibodies | Venture Round | 0 |
| 11/2018 | QurAlis | Seed Round | 5.5M |
| 7/2016 | Akili Interactive Labs | Series B | 42.4M |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 6/2006 | TetraLogic Pharmaceuticals | Series B | 36M |
| 5/2017 | Genuity Science | Series B | 75M |
| 1/2015 | Surface Oncology | Series A | 35M |
| 10/2022 | Inversago Pharma | Series C | 0 |
| 11/2018 | Ribometrix | Series A | 30M |
| 3/2012 | Cytos | Post-IPO Equity | 40M |
| 10/2013 | Opsona | Series C | 0 |
| 5/2022 | Olive Diagnostics | Seed Round | 1.5M |
| 4/2012 | Viridian Therapeutics | Series B | 20M |
| 11/2017 | Fortuna Fix | Series B | 25M |
| 4/2013 | Opsona | Series C | 0 |
| 11/2022 | Casma Therapeutics | Series C | 46M |
| 6/2014 | Viridian Therapeutics | Series B | 7M |
| 12/2013 | Atara Biotherapeutics | Series B | 38.5M |
| 5/2006 | Avidia | Series C | 43.8M |
| 1/2016 | Alector | Series D | 29.5M |
| 8/2021 | Catena Biosciences | Seed Round | 5M |
| 6/2006 | VLST Corporation | Series B | 55M |
| 9/2011 | Theraclone Sciences | Series B | 10.6M |
| 2/2019 | Aetion | Series B | 0 |
| 6/2022 | Senti Biosciences | Post-IPO Equity | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 10/2007 | Allozyne | Series B | 30M |
| 12/2005 | Allozyne | Series A | 3.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 3/2010 | Theraclone Sciences | Venture Round | 1.5M |
| 3/2007 | Theraclone Sciences | Series B | 29M |
| 10/2009 | Epizyme | Series B | 32M |
| 1/2016 | Tizona Therapeutics | Series A | 27M |
| 8/2021 | Genome Medical | Series C | 0 |
| 5/2021 | GPB Scientific | Venture Round | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 11/2014 | Ziarco | Series B | 33M |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 4/2018 | Aetion | Series B | 36.4M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 4/2017 | Science 37 | Series C | 35M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 7/2014 | NexImmune | Venture Round | 3M |
| 5/2018 | Akili Interactive Labs | Series C | 0 |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 1/2004 | Infinity Pharmaceuticals | Venture Round | 25M |
| 5/2020 | Syapse | Series D | 30M |
| 1/2022 | Gandeeva Therapeutics | Series A | 0 |
| 7/2022 | BigHat Biosciences | Series B | 0 |
| 7/2022 | Kernal Biologics | Series A | 0 |
| 6/2022 | ReCode Therapeutics | Series B | 0 |
| 6/2022 | Senti Biosciences | Post-IPO Equity | 0 |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 5/2022 | TileDB | Venture Round | - |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 3/2022 | CancerIQ | Series B | 0 |
| 1/2022 | Gandeeva Therapeutics | Series A | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
